Dublin, Jan. 02, 2018 (GLOBE NEWSWIRE) -- The "H3N2 Infection - Pipeline Insights, 2017" drug pipelines has been added to Research and Markets' offering.

H3N2 Infection-Pipeline Insights, 2017 provides comprehensive insights of the ongoing therapeutic research and development across H3N2 Infection. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of H3N2 Infection by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

Scope of the Report:

  • The report provides a snapshot of the pipeline development for the H3N2 Infection
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the H3N2 Infection
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for H3N2 Infection
  • The report also covers the dormant and discontinued pipeline projects related to the H3N2 Infection

Reasons to Buy:

  • Establish comprehensive understanding of the pipeline activity across this H3N2 Infection to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of H3N2 Infection therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered:

1. Report Introduction

2. H3N2 Infection Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for H3N2 Infection

4. Comparative Analysis

5. Products in Clinical Stage
5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products
8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • AIMM Therapeutics BV
  • Aphios Corp
  • BiondVax Pharmaceuticals Ltd
  • Celltrion Inc
  • FluGen Inc
  • Glide Pharmaceutical Technologies Ltd
  • ILiAD Biotechnologies LLC
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Medicago Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vk7pgw/global_h3n2?w=12



CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs

Primary Logo